0JAV.L

Insmed Incorporated [0JAV.L] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

0JAV.L Stock Summary

Top 10 Correlated ETFs

0JAV.L

Top 10 Correlated Stocks

0JAV.L

In the News

0JAV.L Financial details

Company Rating
-
Market Cap
4.05B
Income
-749.57M
Revenue
305.21M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
912
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-5.87
Forward P/E
-
PEG
-1.61
P/S
15.15
P/B
-14.68
P/C
-
P/FCF
-8.11
Quick Ratio
4.18
Current Ratio
4.71
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-5.34
EPS next Y
-
EPS next Q
-
EPS this Y
36.57%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
12.15%
Revenue last 5Y
17.47%
Revenue Q/Q
5.84%
EPS Q/Q
15.32%
-
-
-
-
SMA20
-8.74%
SMA50
-10.46%
SMA100
-4.03%
Inst Own
-
Inst Trans
-
ROA
-55%
ROE
720%
ROC
-0.6%
Gross Margin
79%
Oper. Margin
-239%
Profit Margin
-258%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
16.585-31.99
52W High
+132.84%
52W Low
+351.13%
RSI
51.16
Rel Volume
0.17
Avg Volume
1.36K
Volume
237
Perf Week
0.68%
Perf Month
-5.71%
Perf Quarter
7.76%
Perf Half Y
0.81%
-
-
-
-
Beta
0.915
-
-
Volatility
1.07%, 4.59%
Prev Close
0.6%
Price
72.18
Change
3.71%

Something similar

Top by Market Cap
FB2A.DE
MSFT
AAPL
BRK-A
LLY.DE
Top Correlated ETFs
BIGT.L
BIOT.L
2B70.DE
2B78.DE
DRDR.L
Top Correlated Stocks
0HKF.L
DAP.DE
FTC.L
KNOW.ST
FORTUM.HE
Similar Market Cap
RBSFY
002613.SZ
603278.SS
1525.TW
UDCD.QA

Company Profile

Healthcare Medical - Pharmaceuticals
  • Volume Average 1.36K
  • Market Capitalization 4.05B
  • Employee 912
  • CEO Mr. William H. Lewis J.D., M.B.A.
  • Headquarters Bridgewater,NJ,US
  • IPO Date 2018-01-29
  • Website https://www.insmed.com

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.